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Summary Mucus glycoproteins of human amniotic fluid were used to generate a monoclonal antibody (MAb)
FW6, which stained the intestine of a 24 week stage fetus.
In adults, 76% ofcolonic adenocarcinomas (13/17) showed strong expression of the FW6 epitope, but it was
not detected in the histologically normal mucosae adjacent to the tumours or in normal left colon mucosa. In
addition, MAb FW6 stained large cell carcinomas of the lung (2/3), gastric carcinomas (5/11), and ovary
adenocarcinomas (3/4).
The expression in carcinomas can also be called ectopic for testing normal tissues. MAb FW6 was also
reactive with pyloric mucus glands, Brunner's glands of the duodenum, Paneth cells of the ileum, pancreatic
ducts, absorptive cells of the right colon, bronchiolar glands, kidney urothelia, and with a restricted number of
normal mucinous tubuli of salivary gland. It was demonstrated to be under the control of the secretion gene
only in intestinal Paneth cells and absorptive cells of the right colon. Comparative histochemical analysis
comprising a panel of MAbs suggests that the corresponding epitope of the MAb FW6 is a type II chain
related carbohydrate structure belonging to the Lex/LeY-antigen family, but is different from short chain Lex
and Ley.
It has become increasingly evident that surface markers of
tumour cells may resemble antigens of fetal cells. These
observations were confirmed by the findings that tumour cells
can re-express antigens which are found at an early stage of
development but are suppressed during the progress of
embryogenesis.
The characterisation of monoclonal antibodies (MAbs)
which react with tumour-associated antigens, has brought
into focus the complex carbohydrate structures of mucin
glycoproteins. Such structures are expressed by both normal
and malignant epithelial cells and are supposed to be highly
immunogenic (Feizi, 1985). In the last decade, our knowledge
of the carbohydrate structures on mucins as well as on
glycolipids has been greatly enriched for this reason (Hako-
mori, 1985; Lloyd, 1986). Some of these carbohydrate anti-
gens have not only been demonstrated in various carcinomas,
embryonic or fetal tissues, but also in human amniotic fluid
and seminal plasma (Hanisch et al., 1985; 1986a, b; 1988).
Most MAbs, directed against the carbohydrate structures
of tumour-associated antigens, were generated against cell-
lines, tumour-extracts or glycolipids extracted from cell mem-
branes.
We used an alternative route by immunising with purified
mucus glycoproteins from human amniotic fluid. The mucins
from amniotic fluid lack any significant blood group A and B
activities as previously shown (Lambotte & Uhlenbruck,
1966), but are rich sources of tumour-associated carbohy-
drate structures, especially sialyl-Lex and sialyl-Lea.
Materials and methods
Monoclonal antibodies
The following MAbs were used as controls in epitope ana-
lysis, immunocytology and immunohistology: CSLEX-1 was
a generous gift from Dr Terasaki (Los Angeles, USA) (Fuku-
shima et al., 1984); AM-3 was kindly provided by Dr C.
Hanski (Berlin, Germany) (Hanski et al., 1990). Both MAbs
were directed to sialyl-Lex. MAbs anti-LeuMl and VimC6 of
the cluster CD15 reacting with Lex were purchased from
Becton Dickinson (Heidelberg, Germany and Boehringer
Mannheim, Germany) respectively. MAb 12-4LE, directed to
Ley, was prepared against the colorectal carcinoma cell line
SW 1116 as described earlier (Bara et al., 1988). Anti-CEA
(Dako, Hamburg, Germany) was used as control MAb for
the detection of protein epitopes. Irrelevant MAbs of differ-
ent isotypes were used as negative controls.
Mucin preparation
Human amniotic fluid was collected during normal delivery
(University Hospital of Gynecology and Obstetrics, Cologne,
Germany) from six healthy women. Fluids were filtered and
centrifuged and supernatants stored at -20°C until used.
For extraction of mucus glycoproteins, amniotic fluids was
pooled and an equal volume of 90% aqueous phenol was
added and incubated at 65°C for 15 min. The aqueous phase
was extensively dialysed against water and lyophilised. The
phenol-extracted material was fractionated by gel filtration
on a Sephacryl S400 column (2.5 x 100 cm), equilibrated and
run with 4 M guanidine hydrochloride, 1 mM EDTA and
1 mM sodium phosphate at pH 7.0 as shown previously
(Hanisch et al., 1988; 1989). The void volume representing
high molecular weight glycoproteins was determined by
adsorption at 280 nm. Respective fractions were pooled, dia-
lysed against distilled water and lyophilised.
Immunisation ofmice andgeneration ofhybridomas
Mice (BALB/C) were first immunised by subcutaneous injec-
tion of 0.1 mg purified mucus-glycoproteins of amniotic fluid
in 0.1 ml of distilled water, mixed with an equal volume of
Freund's adjuvant (Boehringer Mannheim, Germany). Immun-
isation (0.3 mg) was repeated five times with incomplete
Freund's adjuvant (Difco, Detroit, MI, USA) or with ABM-
2 adjuvant system (Sebak, Aidenbach, Germany) containing
0.5 mg trehalose dimycolate, 0.5 mg monophosphoryl lipid
A, 2% oil and Tween 80 in 2 ml PBS. One day after the final
inoculation, spleen cells of immunised mice were fused with
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the HAT-sensitive X63Ag8.653 mouse myeloma cells in the
presence of polyethylene glyco-1500 (Boehringer Mannheim,
Germany) according to the protocols of Kohler and Milstein
(1975) and Stahli et al. (1980).
Clones were selected in HAT medium (1% hypoxanthine/
thymidine/aminopterine, Sigma, Deisenhofen, Germany) con-
taining 5 x 10-5 M 2-mercaptoethanol and 10% fetal calf
serum (FCS, Gibco, Karlsruhe, Germany) in the presence of
mouse peritoneal macrophages. Hybridoma clones were
screened for the production of monoclonal antibodies against
mucins of the pooled human amniotic fluid by the ELISA
technique.
Preparation ofglycopeptides by protease digestion
Native amniotic fluid was incubated with predigested pronase
P from Streptomyces griseus (Serva, Heidelberg, Germany) at
a final concentration of 0.1 mg ml-' in TBS (0.02M Tris,
5 mM CaC12, pH 7.8) at 37°C for 48 h with a further addition
of pronase P after 24 h. Then urea was added to a final
concentration of 6 M, the pH was adjusted to 12 with NaOH,
and phenol extraction was carried out by addition of 1 vol
hot phenol (65°C, 10 min). After phase separation by further
addition of 1 vol distilled water and dialysis, the freeze dried
protease stable glycopeptides from amniotic fluid were frac-
tionated by gel chromatography (2.2 x 80 cm) on Bio-Gel
P30 (Bio Rad, Munchen, Germany), equilibrated with 0.01 M
pyridine acetate (Hanisch et al., 1989). The eluate was col-
lected in 3 ml fractions and registered by colorimetric ana-
lysis of hexose (phenol-sulphuric acid method), sialic acid
(thiobarbituric acid method) or by ELISA using MAb anti-
LeuM1. Glycopeptides found in the excluded fraction were
collected and lyophilised.
Chemical and enzymatical treatment ofglycopeptides
For preliminary biochemical analysis of MAb epitopes, peri-
odate oxidation and sialic acid hydrolysis of carbohydrates
were performed with coated protease-stable glycopeptides in
microtitre plates. In the other experiments, soluble glycopep-
tides were treated in batches.
Coated glycopeptide carbohydrates were partially oxidised
by incubating the wells with 1 mM or 10 mM periodate
(NaIO4) in acetate buffer for 1 h at 25°C in the dark, after a
short wash with 50 mM sodium acetate, pH 4.5 (Woodward
et al., 1985). Following a brief rinse with sodium acetate
buffer the plates were then incubated with 50 mM NaBH4 for
30 min at 22°C and washed with 0.5% BSA/PBS.
Enzymatic hydrolysis of sialic acid of coated glycopeptides
was performed using vibrio cholerae 0.1 U ml-' neuramini-
dase ( = sialidase, Behring-Werke, Marburg, Germany) in
0.05 M sodium acetate, 9 mM CaC12, 0.14 M NaCl, pH 5.5 for
1 h at 370C.
For heat treatment, mucins or glycopeptides were dissolved
in 0.02 M PBS, pH 7.2, at a concentration of 1 mg ml-1, and
incubated at 100°C for 1 h.
Blockage of free amino groups on glycoproteins was per-
formed in 0.1 M tetraborate buffer pH 9.3 containing 0.75
mM 2,4,6-trinitrobenzenesulphonic acid (TNBS) (Serva, Hei-
delberg, Germany) at 22°C for 30 min.
Glycoproteins were also treated with trifluoromethanesul-
phonic acid (TFMS) for 2 h at 0°C according to Sojar and
Bahl (1987). The reaction mixture was neutralised with a
40% pyridine in water at -20°C, subsequently dialysed and
lyophilised.
Enzyme-linked immunosorbent assay (ELISA)
The 96-well microtitre plates (Nunc, Wiesbaden, Germany)
were coated with the selected glycoprotein or glycopeptide
preparation (0.1 mg ml-') in 0.1 M carbonate buffer, pH 9.6
by drying over night at 37TC, and blocked with 0.5% BSA/
PBS (bovine serum albumin/phosphate buffered saline);
0.1 ml of hybridoma tissue culture supernatants were applied
to the wells (1 h, 20°C). Rabbit anti-mouse immunoglobulins
diluted to 1/25 in PBS (Dako, Hamburg, Germany) were
added, followed by alkaline phosphatase anti-alkaline phos-
phatase immunocomplexes (APAAP, 30 min, 20°C). Each
step was followed by washing the wells. The reaction product
was developed using p-nitrophenylphosphate (Sigma, Deisen-
hofen, Germany) in diethanolamine buffer, pH 9.8 (Boeh-
ringer Mannheim, Germany).
Extinction was read at 405 nm by a Flow ELISA reader.
The reduction of antibody binding after chemical and enzy-
matic treatment of the antigen was regarded as significant, if
the measured activities decreased to less than 30% of the
control while more than 80% binding was assigned to a
stable epitope.
Immunocytology ofcell lines, blood and bone marrow smears
Cell lines were cultured in 10% FCS-RPMI with penicillin
and streptomycin, washed in PBS, and coated on 96-well
Terasaki plates by centrifugation (200 g for 10 min). Unfixed
cells, 0.025% glutaraldehyde fixed cells and 0.1% Tween 20
treated cells were incubated with hybridoma supernatant for
1 h. Binding of MAb was visualised by indirect immunoper-
oxidase staining.
Blood and bone marrow from patients with leukaemia or
without haematological disease were taken off. The immuno-
reactivity of the MAbs was tested on viable cells by indirect
immunofluorescence and on routinely prepared, acetone fixed
smears by the APAAP method (Schwonzen et al., 1989).
Immunohistology
Tumour tissues were resected after surgery. Normal gastro-
intestinal tissue was obtained from seven kidney donors
belonging to the following phenotypes: ALe(a +b ), ALe(a-b
AL(a - b - ) L(a +b - ) L(a - b + ), o(a + b - ) oL(a - b +) ALe(a), BLe(a+), BLe(a+) OLe(ab, OLe(b)
Le(a+b-) individuals were considered as non-secretors and
Le(a -b+) as secretors (Oriol et al., 1986). Autopsies were
performed within 5 min of death. Mucosa strips of pylorus-
duodenal junction, Ileum-right colon (or caecum) junction
and sigmoid mucosae were fixed with 95% ethanol and
coiled up into 'Swiss rolls' (Bara et al., 1988).
Other tumour and normal tissues were first fixed in 6%
neutral phosphate-buffered formalin and dehydrated in etha-
nol by standard histological techniques. After embedding all
tissues in paraffin, serial microtome tissue sections (5,um)
were used for comparative immunohistological studies. Reac-
tivity of hybridoma tissue culture supernatants was deter-
mined using a four-step immunoperoxidase technique. After
deparaffinisation in xylene, rehydration through graded etha-
nol, and blocking endogenous peroxidase activity with 2%
H202 in absolute methanol for 30 min, the sections were
incubated as follows: (1) normal swine serum (5% in PBS),
(2) MAb in tissue culture supernatant or mouse ascites fluid
diluted to 1/100 in PBS, (3) rabbit anti-mouse immunoglo-
bulin (2% in PBS), (4) swine anti-rabbit immunoglobulin
(2% in PBS), (5) rabbit peroxidase anti-peroxidase (PAP)
complex. The slides were treated with 0.2 mgml-' 3-amino-9-
ethylcarbazole (Sigma, Deisenhofen, Germany) in 0.02 M
sodium acetate buffer containing 0.01% H202, then counter-
stained with haematoxylin, and mounted in glycerol jelly. All
incubation steps were performed in a moist chamber at 21°C
for 30 min, all polyclonal antibodies were purchased from
Dako (Hamburg, Germany).
Results
Generation and selection ofmonoclonal antibodies
After immunisation with the purified mucus glycoproteins
(mucins), less than 10% of the antibody producing hybri-
domas secreted antibodies against the mucins of amniotic
fluid. For detecting MAbs with carbohydrate specificity, 28
hybridomas were tested on chemically and enzymatically
modified mucus glycoproteins or glycopeptides. Carbohy-MONOCLONAL ANTIBODY FW6 TO A TUMOUR-ASSOCIATED EPITOPE
drate antigens are expected to be resistant (i) protein
modification by blocking of amino groups with TNBS, (ii)
heat denaturation, and (iii) degradation by proteases, but to
be labile to (i) oxidation by sodium periodate, (ii) degly-
cosylation by TFMS, or (iii) hydrolysis by glycosidases.
The hybridoma FW6 secretes antibodies of 1gM class,
which bind to a TNBS-, heat- and pronase-stable epitope on
mucine-derived high-molecular weight glycopeptides. The cul-
ture supernatant of the hybridoma FW6 showed no reactivity
with mild (1 mM) and strong (10 mM) periodate oxidised, or
with TFMS-treated glycopeptides (Table I).
Treatment of coated mucins with vibrio cholerae neur-
aminidase does not reduce antibody binding of MAb FW6 in
contrast to other clones, showing that terminal N-acetyl
neuraminic acid is not involved in the corresponding epitope
of FW6.
Immunocytology
Immunoperoxidase-staining of unfixed, glutaraldehyde fixed
and Tween-20 treated neoplastic cells was performed with the
cell lines of the following origin: colon (CC-1); breast (MDA-
MB231, BT-20); cervix (ME-180); stomach (MC-1, MC-2);
pancreas (AP-10); larynx (HEP-2); kidney (HN-1); myeloid
(HL60, K562, U937); T-lymphoid (735U, 926, CEM, Molt,
Jurkat, HPB-ALL); B-lymphoblastoid (872, 924, 938, 395-8);
Burkitt, BJAB, P3HRI, Daudi, Raji); plasmocytoma (L915);
and Hodgkin (L540, L428KS).
Among the various cell lines examined, staining with
MAbs FW6 yielded no positive result, whereas MAb anti-
LeuM1 showed immunocytological reaction with AP-10, HL-
60, U937, CEM, HPB-ALL, L540, and L428KS. In addition,
MAb FW6 showed no staining of normal bone marrow cells
or of lymphoid, myeloid, erythroid cells or their malignancies
by testing three cases for every diagnosis: AML-M1 (acute
myeloid leukaemias according to FAB classification), AML-
M2, AML-M4, AML-M5, T-ALL (acute lymphoblastic leu-
kaemia), c-ALL, B-ALL, Null-ALL, CML (chronic myeloid
leukaemia) chronic phase, CML-blast crisis, B-CLL (chronic
lymphocytic leukaemia), and bone marrow cells of patients
with non-haematological diseases. A comparative cytofluoro-
metric study of MAb FW6 with MAbs anti-LeuMl and
AM3 on cell line HL-60 is presented in Figure 1.
Immunohistological staining oftumour and normal tissues
The results of the immunoperoxidase assay for the detection
of FW6 epitope in carcinomas, their mucosae adjacent to
colonic tumour, and normal tissues are summarised in Tables
II-V. Testing neoplastic tissues, the FW6 epitope was
strongly expressed in 13 of 17 colon carcinomas, but not in a
single cell of the adjacent non-malignant tissues (Table II,
Figure 2b and c). In well and moderately differentiated
adenocarcinomas the FW6 epitope was typically detected on
the apical cell surfaces and diffusely in the cytoplasm, as well
Table I Biochemical epitope analysis of MAbs FW6 and LEU-Ml
Modified glycopeptides ofamniotic Retainedactivity (%)
fluid with FW6 LeuMI
Pronase P (0.1 mg ml- 1, 42 h) 100 100
Heat (100°C, 1 h) 98 96
Trinitrobenzenesulphonic acid 95 99
Trifluoromethanesulphonic acid 6 11
Periodate (1 mM, 1 h, 25°C) 8 9
Neuraminidase (vibrio cholerae) 110 107
*The test on chemical orenzymatical treated mucins ofamniotic fluid
wasperformed by ELISA technique, stable epitope = measured activity
of antibody binding after chemical and enzymatical treatment of the
antigen retained more than 80% binding, sensitive epitope = measured
activityofantibody bindingafterchemical andenzymatical treatmentof
the antigen decreased to less than 20% of the control; 2,4,6,-
trinitrobenzenesulphonic acid (TNBS) blockage of amino groups;
trifluoromethanesulphonic acid (TFMS) deglycosylation (Sojar et al.,
1987).
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Figure 1 Cytofluorometric analysis of viable cells of the HL-60
cell line, first reacted with MAbs FW6 a, LeuM1 b, and AM-3
c and then with FITC-labelled F(ab')2 of goat anti-mouse
(IgG + M). Negative controls revealed curves identical to a.
as in the secretions of carcinomatous glands. Colonic adeno-
carcinomas without differentiation showed predominantly
intracytoplasmatic staining. MAb anti-LeuM1 (Lex specific)
stained most colon carcinomas tested, MAbs CSLEX-1 and
AM-3 (both sialyl-Lex specific, manuscript in preparation for
AM3) stained all colon carcinomas tested, but in contrast to
MAb FW6 also reacted with the adjacent normal colonic
deep crypt epithelium of few cases (Table II). MAb 12-4LE
(Ley-specific) revealed different binding pattern to MAb FW6
by staining colonic adenocarcinomas, especially in the cases
4, 5 and 12. In contrast to the MAb FW6 epitope, Ley was
expressed in few absorptive cells of the adjacent non-malig-
nant mucosae in case 5.
In fetal colonic mucosa in FW6 epitope was expressed on
the apical cell membranes and in the cytoplasm (Figure 2a).
Testing the normal colonic mucosae the FW6 epitope was
detected in some absorptive cells and a few goblet cells of the
right colon in secretor individuals (Le(a-b+) and Le(a-b-)) in
contrast to the Lea non-secretors (Table III). FW6 antibody
revealed no staining of normal left colon of secretors or
non-secretors (Figure 2b).
MAb FW6 stained most cells of gastric carcinomas in five
of nine cases (Table IV), but it also reacted with goblet cells
and deep pyloric glands in the adjacent and normal stomach
tissue (Figure 2d). The staining of pylorus glands as well as
Brunner's glands in the duodenum was independent of the
ABO and the Lea/Leb blood group status (Table V).
The FW6 epitope was not present in the villosities of
normal ileum, but was detected on the Paneth cells of secre-
tors with the blood group Leb or Le-, and not on the Paneth
cells of the Lea positive individuals (Figure 2e).
MAb FW6, in addition, binds to antigens of ovary adeno-
carcinomas and large cell carcinomas of the lung (Table IV).
Staining of bronchiolar glands and epithelia in the adjacent
and normal lung tissue was noticed.
MAb FW6 did not stain mammary carcinomas, pancreatic
carcinomas, prostate carcinomas and neoplasias of the testes
(Table IV). In two of six normal pancreatic tissues, ductuli
and not the acini showed positive cells (Figure 2f).
Normal kidney does not express the FW6 epitope, whereas
normal urothelia do.
Discussion
Monoclonal antibody FW6, which identifies a periodate-
sensitive, neuraminidase resistant epitope on mucins from
amniotic fluid, differs from our other generated antibodies in
that it discriminates between adenocarcinomas of the colon
and adjacent or normal colonic tissues. The FW6 epitope is
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Table II Immunoperoxidase staining ofcolon carcinomas and non-malignant adjacent tissues with MAbs FW6, 12-4LE,
Anti-Leu Ml, AM3 and CSLEX-1
Colon carcinomas Adjacent non-malignant tissues
MAbs
Sample' FW6 12-4 L-MJ AM3 CSLEXJ FW6 12-4 L-MJ AM3 CSLEXI
I +++ + ++ +++ +++ +
2 +++ n ++ + + n +
3 + n ++ +++ +++ n
4 + _ _ ++ ++
5 - + ++ + + + + + +
6 +++ n ++ +++ +++ - n
7 +++ n + +++ +++ n +
8 ++ n + + + n +
9 ++ n + ++ ++ n n n n
10 - - - +++ +++ n +
11 + + ++ +++ +++ n + +
12 - +++ +++ +++ +++ n n n + n
13 +++ ++ + +++ +++ n n n n n
14 + +++ + + + n n n n n
15 ++ + + +++ +++ n n
16 + ++ +++ +++ +++ n
17 - n - + - n n n
n
'Serial paraffin-embedded sections; 12-4 = 12-4LE, MAb directed to Ley (Bara et al., 1988); L-M1 = anti-Leu MI, MAb
directed to Lex; MAbs CSLEX and AM3 are directed to sialyl-Le' (Fukushima et al., 1984; Hanski et al., 1990); n = not
determined; - = negative finding; positive reactions from + to + + + represent increasing percentage of immunostained
tissue areas: + = 0-33%, + + = 34-66%, + + + = 67% or more.
also expressed by most gastric carcinomas, ovarian carcin-
omas as well as some large cell carcinomas of the lung, but
not by mammary carcinomas. The source of this epitope in
amniotic fluid might be the secretions of the fetal gastrointes-
tinal mucosa rather than the chorionic membrane or the fetal
urine, since the FW6 epitope is strongly expressed by epi-
thelial cells of the small intestine and right colon in the 24
week fetus.
The staining pattern of MAb FW6 indicates that the
expression of this epitope in adenocarcinomas could also be
regarded as ectopic, for it was detected in some cells of
differentiated normal glandular epithelia, such as mucus cells
of pyloric glands, Brunner's glands in the duodenum, ducts
of the pancreas, mucinous tubuli of salivary gland and bron-
chiolar glands.
Regarding the possible antigen structure of MAb FW6,
recognising gastrointestinal malignancies, carbohydrate type
1 and type 2 structures related to blood group antigens have
to be discussed. Immunohistological staining of normal gast-
ric mucosa raises the possibility that the FW6 epitope is
related to type 2 blood group antigens such as H type 2, Lex
and Ley antigens, since it is detected in the deep area of
pyloric glands regardless of the secretor status (Mollicone et
al., 1985; Sakamoto et al., 1989). Thus MAb FW6 did not
detect one of the type 1 antigens (Lea, sialyl-Lea, Leb), which
were almost exclusively detected in the foveolar epithelia of
intact gastric mucosa, corresponding to the secretor status
(Mollicone et al., 1985; Sakamoto et al., 1989).
There are strong arguments against MAb FW6 defining
the well known short chain Lex-antigen of the mentioned
type 2 structures. First, in normal kidney epithelia MAb
FW6 only stained urothelia, but no part of the nephron
system. In contrast, the Lex-antigen is characteristically ex-
pressed in proximal tubules and the loop of Henle (Cordon-
Cardo et al., 1986). Secondly, the monofucosylated short
chain Lex-antigen and short chain sialylated Lex-antigen have
been shown to be constituents of normal colonic mucosa by
other investigations (Fukushima et al., 1984; Itzkowitz et al.,
1986; Sakamoto et al., 1986; Yuan et al., 1987), which is
confirmed by our results. Third, the FW6 epitope is not
found in few Lex and sialyl-Lex positive tumours, and fourth,
MAb FW6 does not stain myeloid (granulocytic) cells.
Antibody FW6 staining of colonic tissues resembles the
pattern published for MAbs FH4 and FH6, which recognise
extended, polyfucosylated (dimeric) Lex and sialylated poly-
fucosylated (dimeric) Lex respectively (Fukushi et al., 1984a,
b). FH4 and FH6 antibodies gave very similar results to
FW6 antibody, in that they were one of the most specific
MAbs reacting with carcinomas of the colon, do not stain
normal colonic mucosa (Itzkowitz et al., 1986), and are only
bound to specific types of cells in gastric and intestinal
mucosa testing normal tissues (Fukushi et al., 1984b). These
Table III Immunoreactivity of MAb FW6 on normal gastrointestinal mucoase of secretor and non-secretor individuals
Non-secretors Secretors
ALe(a+b-) BLe(a+b-) oLe(a+b-) ALe(a-b+) BLe(a-b+) OLe(a-b+) ALe(a-b-)
Pylorus Surface
Glands +++/- +++/- +++ +++/- +++/- +++ +++/-
Duodenum Villosities - - - - - - -
Brunner's
glands +++/- +++/- +++ +++/- +++/- +++ +++/-
Ileum Villosities
Panethcells - - - + +++ +++ +++
Right colon Absorptive
cells -CD -CD -C +C + + +C +/-C +/-C
Goblet cells - - - +/- +/- +/- +
Left colon
Immunoperoxidase method was performed as previously described (Bara et al., 1988); positive reactions from + to + + +
represent increasing intensity; CD = right colon; C = caecum; + ++ /-= simultaneous presence of strong (+ /-= weak)
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Figure 2 Photomicrographs of tissue sections stained with MAb FW6 by immunoperoxidase technique; a, fetal colonic mucosa (24
week stage), reactive with MAb FW6 ( x 330); b, normal left colonic mucosa demonstrating the absence of the FW6 epitope
( x 100); c, moderately differentiated colon adenocarcinoma showing predominantly apical cell surfaces ( x 100); d, normal gastric
mucosa ( x 100), the FW6 epitope is present in the deep corpus glands independent of the individual secretor status, but it is not
detected in the foveolar epithelium; e, normal terminal ileum, demonstrating the expression of the FW6 epitope in Paneth cells of
secretor individuals ( x 436). f, normal pancreas ( x 330), the FW6 epitope is present in pancreatic ducts in some cases, acinar cells
lack staining in all cases tested.
MAbs had not been available for direct comparative histo-
chemical study, but the flow cytometric pattern of MAb
FW6 reaction with myeloid HL-60 cell line does not coincide
with one of MAbs FH4 and FH6 tested by Symington et al.
(1985).
The expression of the FW6 epitope in the Paneth cells of
the ileum and the absorptive cells of the right colon seems to
be under the control of the secretor gene. This conflicts with
the result that the FW6 epitope is found in pylorus glands, in
Brunner's glands and on salivary glycoproteins from non-
secretors. The expression of the FW6 epitope in the latter
cases seems to be dependent on the H-gene coded fucosyl-
transferase. The secretions of salivary gland on the other
hand do not contain H-gene coded fucosyltransferase and,
accordingly, allow definitive conclusions on the secretor gene
dependency of blood group related epitopes (Oriol et al.,
1986). Up to now we do not have an explanation for the
secretor-dependent and independent expression of the FW6
epitope found in the different organs tested.
The distribution pattern of the FW6 epitope in the normal
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Table IV Immunoperoxidase staining of malignant tumours with
MAb FW6
Malignant tumours* Positive cases
Stomach
well differentiated 2/2t
moderately differentiated 1/4
poorly differentiated 1/2
signet-ring 1/1
Breast 0/10
Lung
squamous cell 0/3
large cell 2/3
broncho-alveolar 0/1
mucoepidermoid 1/1
Pancreas
adenocarcinoma 0/5
Prostate
adenocarcinomas 0/4
Ovary
mucinous adenocarcinoma 2/2
serous carcinoma 1/2
Testes
seminoma 0/2
embryonic carcinoma 0/2
teratocarcinoma 0/2
*Serial paraffin embedded tissue sections; t= the number ofpositive
cases to total number of cases tested is shown.
gastrointestinal tract is also very similar to that published for
Ley. Ley-antigen expression for example is very weak or
absent in normal colonic epithelium, but is strongly expressed
in adenocarcinomas (Brown et al., 1984; Abe et al., 1986;
Kim et al., 1986; Sakamoto et al., 1986; Bara et al., 1988).
Le' and extended Ley structures have also been detected in
stomach, duodenum, pancreas and lung (Mollicone et al.,
1985; Sun et al., 1987; Kim et al., 1988; Pour et al., 1988;
Sakamoto et al., 1989). On the other hand, there are many
discrepancies in the distribution of the FW6 epitope and the
Ley, extended Ley, or trifucosyl Ley determinants, which are
recognised by several MAbs: 12-4LE (Bara et al., 1988),
CC-1, CC-2 (Sun et al., 1987), AH6 (Abe et al., 1983), 75.12
(Blaineau et al., 1983), C14/1/46/10 (Brown et al., 1983), F-3
(Lloyd et al., 1983) and KH-1 (Kaizu et al., 1986). For
example, MAbs C14/1/46/10, KH-1, CC-1, CC-2, and AH6
stained acinar cells in half the specimens of normal pancreas
and pancreatic adenocarcinomas (Brown et al., 1984; Sun et
al., 1987; Kim et al., 1988), whereas FW6 does not. It is
questionable why MAb FW6 stains only pancreatic ducts in
a few cases. This needs further investigation.
Most important, the staining pattern of MAb 12-4LE does
not correspond to the one of MAb FW6 in serial tissue
sections of colonic adenocarcinomas. Knowledge concerning
the distribution of Y-antigen and its extended derivatives
outside the gastrointestinal tract and pancreas is very limited
at present. However, in a limited survey by Sun et al. (1987)
MAbs CC-1 and CC-2 reacted with all breast carcinomas
tested, whereas MAb FW6 did not show reactivity at all.
Summarising the results of biochemical epitope analysis
and histological epitope distribution of the MAb FW6, there
Table V Reactivity of MAb FW6 to various normal tissues and
cells
Secretor gene
Tissue Reactivity dependency
Salivary gland
Serous acini
Mucinous tubuli + + + independent
Stomach
Foveolar epithelia
Gastric glands + + + independent
Duodenum
Villi and crypts
Brunner's glands + + independent
Ileum
Villosities
Paneth cells + + + dependent
Right colon
Absorptive cells + dependent
Goblet cells + dependent
Left colon
Absorptive cells
Goblet cells
24 week stage fetus
Small intestine + + n.d.
Colon + + + n.d.
Kidney
Glomeruli
Henle's loop
Urothelia + n.d.
Lung
Alveoli
Bronchiolar glands + n.d.
Bronchiolar epithelia + n.d.
Mammary gland
Pancreas
Interlobular ductuli + + n.d.
Acinus cells
Blood
Erythrocytes
Granulocytes
Lymphocyte
Bone marrow
Testes
Ovaries
n.d. = secretor status not determined.
is strong evidence for the detection of a carbohydrate anti-
gen, which is very closely related to the Lex/LeY-antigen
family, without proving identical staining pattern to a known
antigen on type 2 chain precursors. The definitive structural
characterisation of its carbohydrate epitope is currently
under investigation. MAb FW6 might be of probable diag-
nostic relevance for the detection of colon carcinoma, for the
FW6 epitope is demonstrated in sera from colon carcinoma
patients.
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